MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (NASDAQ:GERN) today announced the presentation of final data from its Phase 2 clinical trial of GRNVAC1, an autologous dendritic cell vaccine targeting telomerase, in patients with acute myelogenous leukemia (AML) at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida.
